Open Access<p>Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway</p>
Author(s) -
Haoyue Hu,
Yanyang Liu,
Songtao Tan,
Xiao Xie,
Jiang He,
Feng Luo,
Li Wang
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s243660
Subject(s) - kras , mapk/erk pathway , cancer research , lung cancer , mek inhibitor , cancer , medicine , chemistry , kinase , colorectal cancer , biochemistry
With a high frequency of 30%, KRAS mutations in patients with non-small cell lung cancer (NSCLC) often lead to their poor response to most anti-cancer therapies. As a multi-target tyrosine kinase inhibitor, Anlotinib shows clinical efficacy against several types of cancer. However, its effects on KRAS mutant NSCLC and the underlying molecular mechanisms remain unclear.